Plasma Cell Leukemia Clinical Trials

18 recruiting

Frequently Asked Questions

Common questions about Plasma Cell Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Not Applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+15 more
Masonic Cancer Center, University of Minnesota200 enrolled1 locationNCT01962636
Recruiting
Phase 2

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05870917
Recruiting

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

Multiple MyelomaAmyloidosisPlasma Cell Leukemia
University of Alabama at Birmingham5,000 enrolled1 locationNCT05556928
Recruiting

European Myeloma Network (EMN) Sample Project

Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell Leukemia+2 more
European Myeloma Network B.V.6,000 enrolled41 locationsNCT06237803
Recruiting
Phase 2

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

Multiple MyelomaPlasma Cell Leukemia
University of Utah40 enrolled1 locationNCT06517017
Recruiting

Registry for Adults With Plasma Cell Disorders (PCD's)

Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+6 more
UNC Lineberger Comprehensive Cancer Center2,000 enrolled1 locationNCT03717844
Recruiting
Early Phase 1

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University24 enrolled1 locationNCT06730256
Recruiting
Phase 1Phase 2

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Early Phase 1

A Study of CT0596 in Plasma Cell Leukemia

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China27 enrolled1 locationNCT06988059
Recruiting
Phase 2

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07106684
Recruiting
Phase 2

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05979363
Recruiting
Early Phase 1

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)AL Amyloidosis (AL)
Anhui Provincial Hospital36 enrolled1 locationNCT07085559
Recruiting
Phase 2

Allo HSCT Using RIC and PTCy for Hematological Diseases

Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+25 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 1

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Chunrui Li18 enrolled1 locationNCT05219721
Recruiting
Phase 1

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793
Recruiting
Phase 2

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple MyelomaPrimary Plasma Cell LeukemiaExtramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology54 enrolled1 locationNCT06140966
Recruiting

The Norwegian Immunotherapy in Multiple Myeloma Study

Plasma Cell LeukemiaMyeloma, MultipleAL Amyloidosis
St. Olavs Hospital400 enrolled23 locationsNCT06855121
Recruiting
Early Phase 1

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital24 enrolled1 locationNCT06718270